Biological therapy in IBD - Anti-tumor necrosis factor-alpha and others

Schoelmerich, Juergen and Huber, G. (2003) Biological therapy in IBD - Anti-tumor necrosis factor-alpha and others. DIGESTIVE DISEASES, 21 (2). pp. 180-191. ISSN 0257-2753, 1421-9875

Full text not available from this repository. (Request a copy)

Abstract

Currently used standard treatment in IBD is effective and sufficient for the majority of patients. Published numbers regarding therapy refractoriness are probably related to referral centers and not representative. Pharmacological optimization of available drugs improves the standard situation further. Biological therapies in a larger meaning are studied intensively, but obviously hopes are to some extent not real. Biological and for some principles clinical effects (i.e. TNF antibodies, CD4 antibodies) are proven, the effects are, however, limited and long-term risks and results are not clarified. Numerous approaches are not clinically relevantly effective which is, in particular, true for those inhibiting single mediators. A number of alternative concepts such as hormones and growth factors could be effective and will be studied further. In particular probiotics may be a development of the future and they belong to the 'biologic treatments' in the true sense. Copyright (C) 2003 S. Karger AG, Basel.

Item Type: Article
Uncontrolled Keywords: ACTIVE CROHNS-DISEASE; INFLAMMATORY-BOWEL-DISEASE; PLACEBO-CONTROLLED TRIAL; RECOMBINANT HUMAN INTERLEUKIN-10; RANDOMIZED CONTROLLED-TRIAL; ESTABLISHED EXPERIMENTAL COLITIS; ENGINEERED HUMAN-ANTIBODY; SIDED ULCERATIVE-COLITIS; PROPRIA T-LYMPHOCYTES; COTTON-TOP TAMARIN; Crohn's disease; ulcerative colitis; tumor necrosis factor-alpha; T lymphocytes; anti-sense; cytokines; growth factors
Subjects: 600 Technology > 610 Medical sciences Medicine
Divisions: Medicine > Lehrstuhl für Innere Medizin I
Depositing User: Petra Gürster
Date Deposited: 23 Jun 2021 09:29
Last Modified: 23 Jun 2021 09:29
URI: https://pred.uni-regensburg.de/id/eprint/39437

Actions (login required)

View Item View Item